Maravai Lifesciences Holdings (MRVI) Research & Development (2020 - 2026)

Maravai Lifesciences Holdings' Research & Development history runs 7 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• On a quarterly basis, Research & Development fell 20.44% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $16.4 million, a 14.02% decrease from a year earlier, with the FY2025 full-year figure at $17.4 million, down 9.46% from the prior year.
• Research & Development improved to $3.9 million in Q1 2026 per MRVI's latest filing, from $3.8 million in the prior quarter.
• Across five years, Research & Development topped out at $5.4 million in Q3 2022 and bottomed at $3.7 million in Q1 2022.
• The 5-year median for Research & Development is $4.6 million (2024), against an average of $4.5 million.
• Biggest YoY gain for Research & Development was 176.93% in 2022; the steepest drop was 45.44% in 2022.
• Year by year, Research & Development stood at $5.0 million in 2022, then dropped by 8.32% to $4.6 million in 2023, then fell by 0.72% to $4.6 million in 2024, then retreated by 16.95% to $3.8 million in 2025, then grew by 2.67% to $3.9 million in 2026.
• Per Business Quant, the three latest MRVI Research & Development figures stand at $3.9 million (Q1 2026), $3.8 million (Q4 2025), and $3.8 million (Q3 2025).